SureTrader SureTrader
Home > Boards > US Listed > Medical - Equipment >

Cytosorbents Corporation (CTSO)

Add CTSO Price Alert      Hide Sticky   Hide Intro
Search This Board:
Last Post: 10/26/2016 8:57:59 AM - Followers: 174 - Board type: Free - Posts Today: 0
About CytoSorbents, CytoSorb, and HemoDefend

CytoSorbents Corporation is a critical care focused therapeutic device company using blood purification to modulate the immune system and fight multi-organ failure in life-threatening illnesses. Its purification technology is based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. In 2011, CytoSorb®, the Company's flagship product, achieved European regulatory approval as an extracorporeal cytokine filter, allowing it to be sold throughout the European Union (E.U.) under the CE Mark, to be used in clinical situations where cytokines are elevated. The goal of the CytoSorb® cytokine filter is to reduce "cytokine storm" in critically-ill patients that could otherwise lead to deadly inflammation, multiple organ failure, immune dysfunction, and often death in common illnesses such as sepsis, trauma, burn injury, acute respiratory distress syndrome, and pancreatitis. The CytoSorb® filter has demonstrated statistically significant reductions in mortality in septic patients at high risk of death in early studies and is now being sold in Germany, Austria and Switzerland for the treatment of critical care illnesses, with availability in other E.U. countries planned in the future, assuming adequate and timely funding, and continued positive results from clinical studies.

HemoDefend is a development-stage blood purification technology platform for the blood transfusion industry intended to reduce transfusion reactions and safeguard the quality and safety of the blood supply. The HemoDefend technology utilizes the Company's polymer bead technology to remove many substances, such as antibodies, free hemoglobin and inflammatory mediators that can cause potentially serious and sometimes fatal transfusion reactions.

CytoSorb® and HemoDefend are just two of a number of different polymers the Company has designed for various medical applications, including improved dialysis, reduction of post-surgical complications in cardiac surgery, treatment of inflammatory and autoimmune disorders, radio-imaging contrast removal in imaging and interventional radiology procedures, and the treatment of rhabdomyolysis, drug overdose, and others. Additional information is available for download on the Company's website:


CytoSorb® - A First-in-Class Cytokine Filter Approved in the European Union


CytoSorb® is a potentially breakthrough critical care immunotherapy that attempts to address one of the most challenging unmet medical needs in medicine…the ability to prevent or mitigate multiple organ failure - the leading cause of death in the intensive care unit (ICU) from any cause.

In response to life-threatening conditions such as sepsis and infection, trauma, serious burn injuries, severe lung injury, and pancreatitis, the body frequently overreacts and produces a massive excess of cytokines, or “cytokine storm”. Cytokines normally help the body cope with injury, but at these levels, cytokine storm is toxic to the body, driving severe inflammation and a cascade of pathophysiologic changes in the body that cause cell damage, organ failure and often death. It follows that reduction of cytokine storm may limit this cascade of events, thereby reducing the severity of illness, and helping patients recover and survive. Until recently, however, there were no effective ways to reduce cytokine storm broadly.

CytoSorb® is a first-in-class extracorporeal cytokine filter, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated. It is compatible with standard hemodialysis machines and blood pumps found in most hospitals. Blood is pumped out of the body, through the CytoSorb® cartridge that contains the company’s proprietary blood compatible porous polymer beads, and the “purified” blood is recirculated back to the patient. In a six hour period, a patient's entire blood volume can be treated approximately 20 times.

CytoSorb® is clinically proven to reduce cytokine storm in the company's multi-center, randomized, controlled European Sepsis Trial conducted in Germany. Treatment was safe and well-tolerated in more than 300 human treatments in very sick patients with the worst forms of sepsis and lung injury, and treatment has been safe in nearly 1,500 human treatments overall. Early data suggests that CytoSorb® can reduce organ injury and improve survival in patients at high risk of cytokine injury, particularly those patients with very high cytokine levels, and patients older than age 65.

CytoSorb® has now been used successfully in many conditions where deadly inflammation can lead to organ injury and failure. We are seeing strong interest in the following clinical applications:


There are more than 100 key opinion leaders in Germany, Austria, and Switzerland (our direct sales territories) who are either using or committed to using CytoSorb in clinical practice or clinical studies. More than 30 investigator-initiated studies in a diverse set of applications are being planned, with many already enrolling patients. In the United States, the U.S. Air Force is funding a 30-patient, FDA-approved randomized controlled human trauma pilot study.

As these other independent studies progress, CytoSorbents collaborates with Dr. John Kellum at the University of Pittsburgh Medical Center, and is sponsoring clinical studies in the area of severe sepsis and septic shock, the result of an overzealous immune response to a severe infection such as pneumonia or a ruptured appendix. Severe sepsis and septic shock are collectively a top ten cause of death worldwide, afflicting approximately 27 million people annually, killing approximately 1 in 3 patients despite the best medical care. CytoSorbents is conducting clinical trials in Europea and currently has an FDA-approved IDE application to run a small sepsis trial in the U.S.. The company will look to conduct a U.S. pivotal sepsis study in the future as a key step towards U.S. FDA approval.

Because of the versatility of CytoSorb®, there are many other potential applications of the technology outside of critical care medicine as well. In particular, CytoSorb® has been used many times intraoperatively during open heart surgery, where the heart must be stopped in order to operate on it, while the blood is pumped outside of the body by a heart-lung machine that oxygenates the blood and pumps it back to the rest of the body. This procedure can result in the production of inflammatory mediators such as cytokines, as well as hemolysis and the release of free hemoglobin into the blood. This can result in inflammation and post-operative complications such as failure to wean from mechanical ventilation and kidney failure. There are more than 1 million open heart surgeries each year in the U.S. and E.U. combined, with an addressable market of more than $1 billion for CytoSorb®.

Another application is in cancer immunotherapy. Cancer cachexia is a wasting condition that occurs in most cancers that leads to rapid uncontrolled weight loss, anorexia, and physical debilitation. Patients lose the physical reserve needed to tolerate treatment and fight the cancer. Because CytoSorb® can remove a broad range of cytokines and other inflammatory mediators that drive cancer cachexia, it may be very helpful in this condition. CytoSorbents is exploring this application, as well as the use of CytoSorb® as a primary cancer immunotherapy to kickstart the immune system to attack cancer, with researchers at the University of Pennsylvania School of Veterinary Medicine.

CytoSorb® is being sold for clinical use in the European Union and in countries outside of the European Union that accept European CE Mark approval such as India, Russia, Turkey and others. The total addressable market for CytoSorb® in critical care applications such as sepsis, burn injury, trauma, ARDS, pancreatitis and other diseases is estimated at $10-15 Billion in the U.S. and Europe alone.


From Shareholder's Letter

Goals for 2014

We have laid out an ambitious, yet potentially achievable, agenda for the next two years. Some of our highest priorities are:

  • Greater awareness of our story and technology through increased media exposure and improved investor relations
  • Revenue growth and increased product adoption in our direct sales territories
  • Distributor agreements for CytoSorb in Europe and elsewhere
  • Strategic partnerships for our pipeline products
  • Non-dilutive funding from grants and other programs
  • Commencement of a U.S. based trial
  • Clinical data and new clinical applications with data being presented at key scientific conferences
  • Improving liquidity and institutional sponsorship of our stock with potential up-listing to a national stock exchange

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
CTSO News: CytoSorbents Congratulates Kathleen Bloch as NJBIZ Public Company Chief Financial Officer of the Year 10/17/2016 07:00:00 AM
CTSO News: CytoSorbents to Present at the 2016 BIO Investor Forum 10/14/2016 07:00:00 AM
CTSO News: Current Report Filing (8-k) 10/11/2016 05:14:49 PM
CTSO News: CytoSorbents and Foxx Medical Begin Saving Lives in Chile with CytoSorb® 10/11/2016 08:00:00 AM
CTSO News: CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial 10/05/2016 07:00:00 AM
#7728   Aegis Capital new buy recommendation on $20 dah174174 10/26/16 08:57:59 AM
#7727   Excited to see Q3 results. I am hoping DebitsAndCredits 10/25/16 07:58:23 PM
#7726   This needs just a spark to explode....fundamentals are SABAI 10/19/16 03:59:09 PM
#7725   NEWS -- CytoSorbents Congratulates Kathleen Bloch as NJBIZ Paulness 10/17/16 09:38:06 AM
#7724   NEWS -- CytoSorbents to Present at the 2016 Paulness 10/14/16 08:56:19 AM
#7723   Keynes said "when the facts change, I change. cars100cars 10/12/16 03:55:09 PM
#7722   Sounds like some posters here got burned buying Pip611 10/12/16 06:27:25 AM
#7721   cars I was a shareholder in this company years snow 10/12/16 05:29:39 AM
#7719   I did it is still a pos stock, dr_lowenstein 10/11/16 06:01:25 PM
#7718   Snow, rapid revenue acceleration is just beginning for cars100cars 10/11/16 01:59:58 PM
#7717   cars A market cap this is roughly 20 snow 10/11/16 12:50:02 PM
#7716   NEWS -- CytoSorbents and Foxx Medical Begin Saving Paulness 10/11/16 09:27:47 AM
#7715   CytoSorbents and Foxx Medical Begin Saving Lives in dah174174 10/11/16 08:47:17 AM
#7714   Snow, your numbers are two quarters behind. The cars100cars 10/10/16 08:48:55 AM
#7713   The market seems to agree with my "nonsense" SABAI 10/07/16 04:14:23 PM
#7712   cars Here are the relevant audited numbers that are available: snow 10/07/16 11:44:26 AM
#7711   Your email I assume was in regards to vinovista 10/07/16 09:57:05 AM
#7710   You're right. 140% increase in product sales revenues cars100cars 10/07/16 09:51:04 AM
#7709   Email from Dr. Chan dah174174 10/06/16 10:02:06 AM
#7708   BOGUS EMAIL CIRCULATING -- NOT RELATED TO CYTOSORB cars100cars 10/05/16 06:07:39 PM
#7707   Relax cars and have a Kit Cat ;-)im SABAI 10/05/16 06:03:14 PM
#7706   I added 25% more shares today on the Millstone 10/05/16 03:41:05 PM
#7705   cars "Revenues are accelerating at a terrific rate." When snow 10/05/16 03:29:08 PM
#7703   Shorts are running away. Tight stops have been cars100cars 10/05/16 02:48:18 PM
#7702   Back to 5.41 50ma imo. SABAI 10/05/16 12:35:43 PM
#7701   Its like fluff news. We all know that SABAI 10/05/16 12:31:28 PM
#7700   I can't imagine what the hell is going rufus8421 10/05/16 12:10:12 PM
#7699   This news was not well received. Why? snow 10/05/16 11:36:34 AM
#7698   NEWS -- CytoSorbents Announces Positive Top-line Safety Data Paulness 10/05/16 09:42:07 AM
#7697   Case of the week 39/2016 andy55q 10/05/16 08:21:09 AM
#7696   NEWS -- International Marketing of CytoSorb® Commences at Paulness 10/03/16 08:46:30 AM
#7695   These testimonials on the new homepage are highly SABAI 09/29/16 12:10:30 PM
#7694   NEWS -- New CytoSorbents Website Highlights Global Growth Paulness 09/29/16 08:52:59 AM
#7693   Russia Clinical Trial andy55q 09/29/16 08:05:43 AM
#7692   Case of the week 38/2016 andy55q 09/29/16 07:58:14 AM
#7691   Case of the week Archive andy55q 09/26/16 08:29:25 AM
#7690   thanks for passing this on. I was showing Radhiker 09/25/16 02:18:11 PM
#7689   Arsak web site andy55q 09/23/16 07:41:36 PM
#7688   NEWS -- CytoSorbents Expands CytoSorb® into Iran with Paulness 09/23/16 09:34:26 AM
#7687   Case of the week 37/2016 andy55q 09/20/16 09:49:13 PM
#7686   NEWS -- CytoSorbents Sponsors Sepsis Heroes Gala in Paulness 09/15/16 08:33:04 AM
#7685   Great volume lately and a steady rise. I Pip611 09/14/16 08:44:00 PM
#7684   Terumo is huge Boys n girls ;-) GLA SABAI 09/12/16 02:18:12 PM
#7683   seems like a new deal every week and Pip611 09/12/16 11:55:43 AM
#7682   NEWS -- Terumo Cardiovascular Group and CytoSorbents Announce Paulness 09/12/16 09:11:51 AM
#7681   NEWS -- CytoSorbents Advances War On Sepsis with Paulness 09/08/16 07:21:39 AM
#7680   NEWS -- CytoSorbents to Present at the 2016 Paulness 09/07/16 07:52:10 AM
#7679   nice accumulation these days - maybe a run Pip611 09/06/16 01:59:18 PM
#7678   Good call....golden cross happening today! dah174174 09/06/16 01:49:01 PM
#7677   GOLDEN CROSS MA 200 & 50 next week. SABAI 09/03/16 07:57:58 AM